Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 13/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749822 | 0.94 | CMA1 (0.45) | CMA1ELANECFDEPHX1 | |
| SCHEMBL12529610 | 0.91 | CMA1 (0.43) | CMA1ELANEMEN1KMT2A | |
| SCHEMBL12021195 | 0.88 | CFD (0.41) | CFDXIAPBIRC3 | |
| SCHEMBL12303272 | 0.87 | BIRC2 (0.41) | CMA1ELANEMEN1KMT2AXIAP | |
| SCHEMBL2579341 | 0.87 | BIRC2 (0.41) | CMA1ELANEMEN1KMT2AXIAP | |
| SCHEMBL15424291 | 0.87 | CMA1 (0.40) | CMA1ELANEMEN1KMT2AXIAP | |
| SCHEMBL12303273 | 0.87 | CMA1 (0.40) | CMA1ELANEMEN1KMT2AXIAP | |
| SCHEMBL12021498 | 0.85 | CFD (0.39) | ELANECFDXIAPBIRC3 | |
| SCHEMBL14001894 | 0.85 | CFD (0.39) | ELANECFDXIAPBIRC3 | |
| SCHEMBL16509045 | 0.83 | TP53 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968590-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-7456209-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048183-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC2, API5 | CMA1 1839/4885ELANE 397/4885CFD 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.